Takashi Seto
Overview
Explore the profile of Takashi Seto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
253
Citations
10731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakagawa K, Garon E, Seto T, Nishio M, Aix S, Paz-Ares L, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39622410
Introduction: RELAY, a global double-blind, placebo-controlled phase 3 study (NCT02411448) found statistically significant improvement in progression-free survival (primary end point) for ramucirumab (RAM) plus erlotinib (ERL) (RAM + ERL) in...
2.
Wolf J, Hochmair M, Han J, Reguart N, Souquet P, Smit E, et al.
Lancet Oncol
. 2024 Oct;
25(10):1357-1370.
PMID: 39362249
Background: Capmatinib has previously shown activity in treatment-naive and previously treated patients with non-small-cell lung cancer (NSCLC) and a MET exon 14-skipping mutation (METex14). Here, we report the final outcomes...
3.
Solomon B, Dagogo-Jack I, Lee S, Boyer M, Ramalingam S, Carcereny E, et al.
JTO Clin Res Rep
. 2024 Jul;
5(7):100685.
PMID: 39034968
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in -positive or -negative advanced NSCLC, respectively. Methods: Starting...
4.
Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, et al.
Int J Clin Oncol
. 2024 May;
29(8):1142-1151.
PMID: 38758397
Background: MET exon 14 skipping mutations occur in 3-4% and MET high amplifications occur in < 1% of patients with non-small-cell lung cancer (NSCLC). Crizotinib, a selective ATP-competitive small-molecule inhibitor...
5.
Nogami N, Tokito T, Zenke Y, Satouchi M, Seto T, Saka H, et al.
Invest New Drugs
. 2024 Feb;
42(1):136-144.
PMID: 38300341
Background: Part E of the KEYNOTE-011 (NCT01840579) study assessed the safety and antitumor activity of pembrolizumab plus platinum-etoposide chemotherapy in Japanese patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC)....
6.
Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, et al.
Transl Lung Cancer Res
. 2023 Sep;
12(8):1702-1716.
PMID: 37691865
Background: An exploratory, proof-of-concept, liquid biopsy addendum to examine biomarkers within cell-free DNA (cfDNA) in the RELAY phase 3, randomized, double-blind, placebo-controlled study was conducted. RELAY showed improved progression-free survival...
7.
Kenmotsu H, Yamamoto N, Misumi T, Yoh K, Saito H, Sugawara S, et al.
J Clin Oncol
. 2023 Sep;
41(34):5242-5246.
PMID: 37656928
JCO The JIPANG study is an open-label phase III trial evaluating the efficacy of pemetrexed plus cisplatin (PemP) versus vinorelbine plus cisplatin (NP) as adjuvant chemotherapy in patients with stage...
8.
Yoshida T, Kumagai T, Toyozawa R, Katayama R, Nishio M, Seto T, et al.
Cancer Sci
. 2023 Jul;
114(9):3698-3707.
PMID: 37434391
The phase 2, single-arm, multicenter, open-label J-ALTA study evaluated the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non-small-cell lung cancer (NSCLC). One expansion cohort of J-ALTA...
9.
Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, et al.
Transl Lung Cancer Res
. 2023 Jul;
12(6):1167-1184.
PMID: 37425411
Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as erlotinib, are standard-of-care for patients with mutation-positive non-small-cell lung cancer (NSCLC), but most patients progress within 1 year. Previously,...
10.
Oku Y, Toyokawa G, Wakasu S, Kinoshita F, Takamori S, Watanabe K, et al.
Cancer Med
. 2023 May;
12(13):14327-14336.
PMID: 37211905
Background: Immunotherapy has become a standard-of-care for patients with non-small-cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death-1, have been shown to be useful in selecting patients...